HONG KONG – Three-year old Chinese novel monoclonal antibody (MAb) developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. The deal comes on the heels of closing a $20 million series A financing funded by local investors.